Wells Fargo Maintains Overweight on Blueprint Medicines, Raises Price Target to $115
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila has maintained an Overweight rating on Blueprint Medicines (NASDAQ:BPMC) and increased the price target from $86 to $115.
December 19, 2023 | 1:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo analyst Derek Archila reaffirmed an Overweight rating on Blueprint Medicines and raised the price target to $115, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst typically suggests a bullish view on the stock's future performance, which can positively influence investor sentiment and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100